Abstract: A postbiotic preparation for pelvic floor muscle rehabilitation and a preparation method and application thereof. A strain of Lactobacillus plantarum Nice-02 is successfully obtained, and a postbiotic preparation product is successfully developed based on the strain.

Abstract: A composition for use in enhancing efficacy of immunotherapy for colorectal cancer in a subject in need thereof includes an effective amount of (1) any one or more of Lactobacillus gallinarum. Roseburia intestinalis, and Streptococcus salivarius K12; and (2) a physiologically acceptable excipient.

Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Abstract: A composition for treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-23 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.

Abstract: A “triple-killer” cancer treatment is provided. Live, cancer stem cells carrying an oncolytic virus expressing an immunomodulator are re-programmed to die within a desired time frame after administration to a subject. The cancer treatment (1) releases a cancer antigen cocktail that creates cancer antibodies in the subject, (2) kills cancer tumor cells in the subject through release of the oncolytic virus itself, and (3) kills additional cancer tumor cells in the subject through the expression of the immunomodulator, the treatment further providing an immunological memory response. The oncolytic virus is amplified in the cancer stem cell itself, before, during, and after the administration, avoiding the toxicity associated with a pure administration of the immunomodulator. The oncolytic virus is constructed to selectively replicate in the tumor/tumors stem cells of the subject, resulting in their death and release of tumor antigens to augment immune response in the triple-killer treatment.

Abstract: The present disclosure relates to a yeast ?-Glucan emulsion for use in prevention or treatment of herpes simplex virus infection, in particular wherein the emulsion comprises an emollient agent, wherein the emollient agent is selected from: squalane, butter, hemp oil, or mixtures thereof. The present disclosure relates to yeast ?-Glucan emulsion with anti-herpetic activity, in particular a face topical composition, more in particular lipstick/face stick/lip or face balm/roll on with anti-herpetic properties; method for obtaining and their use thereof. The present disclosure also relates to a face topical composition, preferably antiherpetically active lipstick, or face stick, or an antiherpetic lip or face balm, or an antiherpetic roll on comprising ?-glucans and the use for the prevention and treatment of disorders of the lips and other areas of the face caused by human herpes viruses.

Abstract: The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms.

Abstract: A yeast cell for use in the treatment and/or alleviation of inflammation and/or symptoms caused by inflammation, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown from a yeast cell treated with electromagnetic waves in the range of 1 GHz to 300 GHz, and composition comprising such a yeast cell.

Abstract: The present disclosure relates to an herbal composition and a method of administering the composition including administering the composition in pill or capsule form on a routine basis for the purpose of increasing energy, alertness, clarity, memory, and sexual enhancement in individuals, and particularly in males.

Abstract: A botanical extract of Myrothamnus sp. is used in a method for one or more of: promoting hair growth, increasing hair growth, delaying hair loss, hindering hair loss, and increasing the thickness of hair of a subject, in particular the hair of the eyelashes and/or eyebrows. The method includes administering the botanical extract of Myrothamnus sp. to the subject. The extract is one which is obtained using subcritical water as an extraction solvent. Methods of preparing the botanical extract and compositions comprising the extract are also disclosed.

Abstract: A method of manufacture of a Kratom-derived formulation for oral, and buccal delivery comprising Mitragyna speciosa-derived compounds (e.g., mitragynine) formulated with phospholipids is disclosed. Kratom-derived extracts have dramatically improved organoleptic properties and enhanced bioavailability when formulated with phospholipids as compared to standard extracts. Also disclosed herein are methods of transmucosal administration of the formulation having phospholipids with Kratom-derived substances. The methodology is directly applicable to other botanical extracts as well as other substances requiring improved organoleptic properties.

Abstract: Dietary supplement compositions are provided herein. Also provided herein arc methods for using the dietary supplement compositions as pre-workout supplements or as supplements during a workout.

Abstract: Provided herein are formula compositions for promoting growth and treatment of moderate acute malnutrition or severe acute malnutrition by increasing lean muscle mass in a patient in need thereof, the formula composition having: at least one animal-based amino acid; at least one vegetable-based amino acid; and Cucurbita maxima; wherein the patient is approximately 2 years old to approximately 6 years old.

Abstract: The invention is directed to compositions that include metal-complexed plant compounds. The compositions can be derived from liquid concentrates, extracts, and pomace from plants, such as fruits or vegetables. The compositions can further include additional nutraceutical antimicrobials, antioxidants, and immune boosters. The compositions can be administered to animals to increase animal health, reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, decrease pro-inflammatory cytokine levels, increase anti-inflammatory cytokines, or any combination thereof in an animal. The compositions of the invention exhibit enhanced bioavailability relative to control compositions that do not contain the metal-complexed compounds.

Abstract: Use of Cistanche tubulosa extract in preparation of a medicament for relieving dry eye symptoms. Said symptoms include ocular burning, itching, stinging, excess watering, foreign body sensation, pain, redness, photophobia and blurred vision.

Abstract: The present invention relates to a composition for oral use comprising chondroitin sulphate, an extract of Prunus dulcis and optionally honey, for the treatment of gastric and esophageal diseases, in particular of the gastroesophageal reflux disease.

Abstract: A method and composition to extract of several processed herbal medicinal plants and an herbal tea composition for ingestion which contains the extract. The functional herbal extraction method and composition is used to relieve the symptoms of flu. This composition creates a synergy between different ingredients that works to suppress flu symptoms including headaches, cough, fever, sore throat and yellow phlegm. The composition comprises of Houttuynia cordata, Chrysanthemum, Paeoniae rubra, Coltsfoot flower, Gypsum, Pumice, Licoriei, and Honeysuckle. The effectiveness of the herbal tea is at least partially dependent on the desired means of preparation and administering the composition.

Abstract: Bioavailable compositions comprising nanoparticulated ingredients in aqueous solution, and methods of making the same. Such a composition may include a water solvent. The composition may also include a nanoparticulated ingredient selected from a list comprising glutathione, l-cysteine, and curcumin. The water solvent may comprise ultrapure water prior to addition of the nanoparticulated ingredient.

Abstract: The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include administering a dose of terlipressin to the patient if the patient has a baseline model end stage liver disease (MELD) score <35, the patient has a serum creatinine (SCr)<5 mg/dl, the patient has an ACLF Grade <3, or a combination thereof and/or monitoring the patient's oxygenation level (SpO2) before and during treatment with the terlipressin.

Abstract: The present invention relates to a composition containing: a compound represented by the following Formula (1): or, a salt thereof, or a solvate thereof; a liquid additive; and optionally an oily component.

Abstract: The present invention relates to Griffithsin (GRFT) for use in a method of preventing or treating infections with respiratory viruses, wherein the GRFT is encapsulated. A preferred embodiment is a combination of targeted nanocarrier-mediated delivery of GRFT and non-encapsulated GRFT to GLR-positive cells infected with, or susceptible to infection with, a respiratory virus.

Abstract: A biological polypeptide applied to inhibition of intracellular lipid accumulation and a synthesis method thereof are provided. An amino acid sequence of the polypeptide is shown in SEQ ID NO: 1 in sequence listing. The polypeptide has relatively high target affinity and high activity, and can exhibit remarkably high activity at extremely low dosages and concentrations. The polypeptide inhibits binding of clusterin and sterol O-acyltransferase by exerting competition on the clusterin to reduce the activity of the sterol O-acyltransferase, so as to achieve functions of controlling physiological metabolism in organisms, such as relieving lipid accumulation in hepatocytes, resisting tumor occurrence, assisting anti-cancer drugs in inhibiting tumor growth, and the like.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: The present disclosure provides compositions including rhApoE2 and methods of using the same to improve neuronal glycolysis, synaptic activity, and learning and memory in subjects with or at risk for neurodegenerative diseases, e.g., Alzheimer's Disease, and/or for preventing or treating a metabolic disease such as diabetes, obesity, and cardiovascular disease.

Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Abstract: Methods of treating a microbial contamination are disclosed. Methods of eliminating or inhibiting proliferation of a target microorganism at a target site are also disclosed. The methods include administering a thermally stable preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution and administering a buffer to a target site. The peptide has a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence. The peptide is configured to self-assemble into a hydrogel.

Abstract: The invention relates to pharmaceutical compositions comprising HLA fusion proteins for use in treating neoplastic disease. The invention also provides combination medicaments comprising both HLA fusion proteins and checkpoint inhibitors, for use in treating cancer.

Abstract: The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.

Abstract: Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of a renal disease or condition, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using an ActRII antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

Abstract: The present application relates to a method for treating a human subject suffering from an enteric neuropathy such as Hirschsprung disease (HSCR) or intestinal hypoganglionosis through the administration of an effective dose of a combination comprising a Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a short chain fatty acid such as butyric acid.

Abstract: Disclosed are agents and methods for treating unwanted or deleterious immune responses. More particularly, the present invention discloses neuritin agents for use in inhibiting plasma cell (PC) differentiation, reducing the number of autoreactive B cells, treating, or inhibiting the development or progression of, autoreactive B cell disorders including B cell-mediated autoimmune diseases and IgE-mediated disorders and of monocional gammopathies and PC dyscrasias.

Abstract: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.

Abstract: The present disclosure provides methods of treating a blood cancer, such as multiple myelona, by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion.

Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

Abstract: The present disclosure provides methods and compositions for treating patients with diabetes mellitus and/or obesity.

Abstract: The present invention provides a combination comprising: (a) a first component which is a Nurr1 agonist; and (b) at least one additional component selected from: (i) an aldosterone antagonist; (ii) an insulin modulator; and (iii) a sulfonylurea. Said combinations are suitable for the treatment of stroke and other neurodegenerative and neuroinflammatory disorders and for treating and/or preventing ischemia and/or reperfusion injury in various vital organs, including the brain and the heart. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.

Abstract: The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.

Abstract: The invention disclosed herein related to an oral, algal oil-based, gastro-intestinal tract permeable peptide composition. Particularly, the invention relates to the oral, water in algal oil-based, peptide compositions for the treatment of glucose metabolic disorders comprising peptides that generally degraded in GIT, a protease inhibitor and algal oil enriched with stabilized DHA along with pharmaceutically acceptable excipients, wherein protease inhibitor forms stoichiometric complex with the protease active site with activity of 5000 to 10,000 BAEE units per mg protein.

Abstract: The present invention relates to compositions, methods, kits and dosage forms comprising a colloidal particle and optionally FVIII. The invention also relates to compositions, methods, kits and dosage forms for treating haemophiliac patients with a deficiency in FVIII, who may or may not have inhibitors to FVIII.

Abstract: This disclosure provides a beverage composition that includes collagen peptides that can be used to improve skin, joint and/or hair health.

Abstract: A method of treating a keloid in a subject, comprising: applying a pharmaceutical composition to a keloid or an area at risk of forming a keloid in a subject, wherein the composition includes an effective amount of a hyaluronan and an effective amount of a collagen, the weight ratio per unit volume of the hyaluronan to the collagen being greater than 1.

Abstract: Ocular antimicrobial compositions and methods and method of use thereof are provided. The compositions incorporate photoactive heterojunction materials can be incorporated into a suitable carrier, alone or in combination with an enzyme capable of generating ROS upon contact with the eye for the treatment of ocular conditions. The method includes contacting the eye of a subject in need thereof, the subject has or has been diagnosed with microbial keratitis, with an effective amount of the disclosed composition. The method further includes contacting the composition in the subject's eye with near infrared radiation (NIR).

Abstract: The invention provides a method of treating or preventing pain in a subject in need thereof. The method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase (10) or carbonic anhydrase (11) such that the nucleic acid is expressed to produce carbonic anhydrase (10) or carbonic anhydrase (11). Alternatively, the method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding a carbonic anhydrase (8) fragment such that the nucleic acid is expressed to produce the carbonic anhydrase (8) fragment.

Abstract: The present invention relates to a composition for inhibiting teratoma formation or growth, comprising tissue inhibitor of metalloproteinase 1 (TIMP-1) or tissue inhibitor of metalloproteinase 2 (TIMP-2) as an effective component. A pharmaceutical composition for inhibiting teratoma formation or growth comprising TIMP-1 or TIMP-2 as an effective component according to the present invention, when used in stem cell therapy, can inhibit the formation and growth of teratomas caused by undifferentiated pluripotent stem cells, without affecting the differentiation potential thereof, and thus can be advantageously used as a combination drug in combination with a stem cell drug.

Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.

Abstract: A combination medicament comprising: a particle comprising an amphiphilic polymer in which a hydrophobic segment is poly(hydroxy acid) and a hydrophilic segment is polysaccharide, and a cancer antigen; and an immuno-stimulating factor, can be used so that the particle and the immuno-stimulating factor are separately administered to a subject, thereby allowing for enhancement in treatment and/or prevention of cancer effect.

Abstract: The disclosure relates to a liposome packaged RNA replicon encoding IL-12. Included are methods for preparing and administering the liposome packaged RNA replicon encoding IL-12.

Abstract: The present invention discloses a recombinant adenovirus vector of a replication-defective human adenovirus (HAdv85C5) or a bovine adenovirus (BAdv85C5) comprising a recombinant adenovirus vector having a heterologous DNA segment encoding mycobacterial Ag85B-p25 epitope (SEQ ID NO: 1), mycobacterial Ag85B-p25 epitope fusion of autophagy-inducing peptide-C5 (SEQ ID NO: 2), or a substantially homologous functional fragment thereof. The vector, having a heterologous DNA segment of SEQ ID NO: 3, SEQ ID NO: 4, or a substantially homologous functional fragment thereof, is an effective vaccine for therapeutically or prophylactically immunizing a subject for protection of infections by various microorganisms, especially Mycobacterium tuberculosis (Mtb), which causes the widespread tuberculosis. Methods of uses and pharmaceutical composition matters are within the scope of this disclosure.